A 71-year-old man on hemodialysis was admitted for castration-resistant prostate cancer.
He received chemotherapy with docetaxel(60mg/m2 every 3 weeks)and prednisolone(10mg/day). As severe adverse reactions due to chemotherapy were not encountered, he could receive chemotherapy in our outpatient clinic. A total of four courses of chemotherapy resulted in a 56% reduction in PSA, which was judged as PR. Chemotherapy with docetaxel and prednisolone can be safely carried out for a patient with castration-resistant prostate cancer, even while on hemodialysis with the usual dose of docetaxel.
Written by:
Ito H, Inamura S, Taga M, Tsuchiyama K, Kusukawa N, Oyama N, Akino H, Yokoyama O. Are you the author?
Dept. of Urology, University of Fukui, Japan.
Reference: Gan To Kagaku Ryoho. 2013 Sep;40(9):1245-7.
PubMed Abstract
PMID: 24047790
Article in Japanese.
UroToday.com Prostate Cancer Section
